Meghanath Yenni/LinkedIn
Aug 4, 2026, 17:03
Meghanath Yenni: Anticoagulant Reversal in Clinical Practice
Meghanath Yenni, Consultant Physician at Medicover Hospitals, shared a post on LinkedIn:
”Anticoagulant Reversal in Clinical Practice:
As anticoagulant use continues to increase, clinicians are encountering more patients with major bleeding, intracranial hemorrhage, and urgent procedures requiring rapid reversal.
A recent 2026 New England Journal of Medicine review provides a practical, evidence-based update on the currently available antidotes and how they should be used.
- Reserve reversal agents for life-threatening or uncontrolled bleeding, or when emergency surgery cannot be delayed.
- Warfarin: Rapid reversal requires IV vitamin K plus 4-factor prothrombin complex concentrate (4F-PCC).
- Unfractionated heparin: Protamine remains the antidote of choice. It partially reverses LMWH and has no effect on fondaparinux.
- Dabigatran: Idarucizumab provides rapid, specific reversal, although delayed dabigatran rebound may occur in some patients.
- Factor Xa inhibitors (apixaban/rivaroxaban): Andexanet alfa provides targeted reversal in carefully selected patients but should be used judiciously because of thrombotic risk, cost, and limited indications. 4F-PCC remains the most widely used nonspecific alternative when andexanet is unavailable or unsuitable.
Before administering any antidote, ask four essential questions:
- Is the bleeding truly life-threatening?
- Is clinically significant anticoagulant still present?
- Can the procedure safely be delayed?
- Does the patient’s thrombotic risk outweigh the benefit of reversal?
As newer anticoagulants become increasingly common, understanding when—and when not—to reverse anticoagulation is becoming just as important as knowing which antidote to use.”

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments